Why this matters — Three distinct ORTEX data streams converged on SGMT (Sagimet Biosciences) on April 24. Short interest, cost to borrow, and options positioning all shifted simultaneously, creating an unusual multi-signal alignment for this small-cap biotech.
Short Interest Surge. SI % FF hit 11.7% as of April 24. That's up 13.8% in a single week. The daily change alone was 12.2%. Shares short rose to approximately 3.63 million — a meaningful jump from 3.18 million the prior week.
Cost to Borrow Spike. The CTB rate shot to 1.01% APR on April 24 — up from just 0.09% the week prior. That's a 1,118% weekly increase. The move is sharp and abrupt. CTB had traded below 0.50% for most of the prior month before this jump.
Options Sentiment Shift. The put/call ratio hit 0.298 on April 24. That's 3.24 standard deviations above the 20-day mean of 0.193. While still below the 52-week high of 0.591, the move represents the most bearish options posture for SGMT in over a month.
Analysts remain firmly bullish. The consensus is Buy across 8 firms. The mean price target is $25.78 — against a current price of $5.86. HC Wainwright and Guggenheim both carry Buy ratings. The wide gap between target and price adds fuel to the divergence story. Insider activity cuts the other way. Multiple C-suite executives — including the CEO, CFO, and CSO — sold shares in February 2026. Net insider selling over the prior 90 days totalled approximately $395,000. On the institutional side, Marshall Wace entered as a new holder with 780,446 shares as of December 2025. BlackRock added 201,236 shares through March 2026. Both moves may represent hedged or arbitrage-oriented positioning. Utilisation sits at 16.6% — well below its 52-week high of 100% — suggesting borrowable supply exists, but the CTB jump indicates demand for those shares spiked sharply.
SGMT reached 100% utilisation within its 52-week range, indicating prior periods of intense short interest pressure. The current utilisation of 16.6% is far from that level, but the CTB spike mirrors conditions that have preceded utilisation climbs before. Earnings have historically been painful — the last four events all delivered negative 1-day returns, ranging from -3.4% to -15%.
See the live data behind this article on ORTEX.
Open SGMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
